Legalize59765 laws
59765 laws
- § 345. Regulations making exemptions
- § 346. Tolerances for poisonous or deleterious substances in food; regulations
- § 346a. Tolerances and exemptions for pesticide chemical residues
- § 346b. Authorization of appropriations
- § 347. Intrastate sales of colored oleomargarine
- § 347a. Congressional declaration of policy regarding oleomargarine sales
- § 347b. Contravention of State laws
- § 1953. Antidrug program
- § 348. Food additives
- § 349. Bottled drinking water standards; publication in Federal Register
- § 350. Vitamins and minerals
- § 350a. Infant formulas
- § 350a–1. Protecting infants and improving formula supply
- § 350b. New dietary ingredients
- § 350c. Maintenance and inspection of records
- § 350d. Registration of food facilities
- § 350e. Sanitary transportation practices
- § 350f. Reportable food registry
- §§ 21 to 27. Omitted
- § 351. Adulterated drugs and devices
- § 352. Misbranded drugs and devices
- § 353. Exemptions and consideration for certain drugs, devices, and biological products
- § 353a. Pharmacy compounding
- § 353a–1. Enhanced communication
- § 353b. Outsourcing facilities
- § 353c. Prereview of television advertisements
- § 353d. Process to update labeling for certain generic drugs
- § 354. Veterinary feed directive drugs
- § 355. New drugs
- § 355a. Pediatric studies of drugs
- § 355c. Research into pediatric uses for drugs and biological products
- § 355c–1. Report
- § 355d. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
- § 355f. Extension of exclusivity period for new qualified infectious disease products
- § 355g. Utilizing real world evidence
- § 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application
- § 355–1. Risk evaluation and mitigation strategies
- § 356h. Competitive generic therapies
- § 356. Expedited approval of drugs for serious or life-threatening diseases or conditions
- § 356a. Manufacturing changes
- § 356b. Reports of postmarketing studies
- § 356c. Discontinuance or interruption in the production of life-saving drugs
- § 356c–1. Annual reporting on drug shortages
- § 356d. Coordination; task force and strategic plan
- § 356e. Drug shortage list
- § 356f. Hospital repackaging of drugs in shortage
- § 356g. Standards for regenerative medicine and regenerative advanced therapies
- § 356j. Discontinuance or interruption in the production of medical devices
- § 356l. Advanced manufacturing technologies designation program
- § 356–1. Accelerated approval of priority countermeasures